Background
==========

Rett Syndrome (RTT) is a neurodevelopmental disorder characterized by loss of spoken language and hand use, hand stereotypes, and mental retardation \[[@B1]\], and is the second most common genetic cause of severe mental retardation in females \[[@B2]\]. Although mutations in the methyl CpG-binding protein 2 gene (*MECP2*) can be found in 95--97% of individuals with classical RTT and in 50--70% of those with atypical RTT \[[@B1]\], some patients do not carry mutations in this gene, suggesting the existence of other genetic causes of RTT \[[@B3]\].

The cyclin-dependent kinase-like 5 gene (*CDKL5*) is located in the Xp22 region and has been found to be associated with atypical RTT with infantile spasms or early seizures starting in the first postnatal months (Hanefeld variant) \[[@B4],[@B5]\]. *CDKL5* is composed of 20 coding exons and codes for a protein of 1,030 amino acids \[[@B6]\]. *CDKL5* mRNA is highly expressed in the adult human brain, which is indicative of its importance in neuronal function and development \[[@B3]\].

The clinical overlap between patients with mutations in *CDKL5* and patients with RTT caused by mutations in *MECP2* reflects the fact that these genes belong to the same pathway \[[@B7],[@B8]\]. To date, more than 80 cases of pathogenic *CDKL5* mutations have been reported \[[@B9]\], but it is likely that many more exist \[[@B7]\]. The present study investigated mutations in *CDKL5* in a cohort of patients with epilepsy and RTT or other RTT-like phenotypes to improve the diagnostic criteria for these patients and to clarify the pathological mechanisms of *CDKL5* mutations.

Methods
=======

Patients
--------

Patients were referred to our diagnostic laboratory for investigation of *MECP2* gene status. We performed mutation screening of *CDKL5* in 60 females from this group who were negative for mutations and large rearrangements in *MECP2*, and who had current or previous epilepsy, regardless of the age of onset, type, or severity. Among these, eight patients were clinically diagnosed with classic RTT, and one with atypical RTT. Twenty patients were thought to be Angelman-syndrome but they were negative for mutations and deletions in *UBE3A*, and six presented with autistic features. The spectrum of phenotypes of the remaining patients was heterogeneous but with Rett-like features.

These patients were referred by various paediatric neurologists and clinical geneticists throughout Spain, and were included in the present study after signed informed consent forms were obtained from the patients' parents.

One hundred DNA samples from anonymous healthy female individuals were used as normal controls for exons 1, 12, 17 and 21 (200 X chromosomes). The samples were obtained from the Basque Centre for Transfusions and Human Tissues. The samples and associated data were processed and released by the Basque Biobank for Research-OEHUN (<http://www.biobanco.org>) following standard operating procedures with appropriate ethical approval. The control individuals had similar geographic origins to the patients. The whole project was approved by the Ethics Committee of Cruces University Hospital.

Screening for *CDKL5* mutations
-------------------------------

*CDKL5* coding sequences and each intron/exon boundary were amplified by polymerase chain reaction (PCR), using previously described primers \[[@B10]-[@B12]\], with slight modifications of the amplification conditions. The PCR products were analysed using conformation-sensitive gel electrophoresis (CSGE), after silver-staining following our protocols \[[@B13]\]. Sequence analysis of genomic fragments with CSGE mobility shifts was carried out on an ABI PRISM 3130xl automated DNA sequencer (Applied Biosystems). Exons 4 and 6 were sequenced directly.

Rearrangements studies
----------------------

Genomic rearrangements were examined using multiplex ligation-dependent probe amplification (MLPA) kits (P189-A2 and P189-B1, MRC Holland, The Netherlands), according to the manufacturer's protocols.

RNA isolation and reverse-transcriptase PCR
-------------------------------------------

We used cDNA to study mutations/variations in exons 8 and 12. Total RNA isolation and cDNA synthesis were performed as described previously \[[@B13]\]. The region from exon 8 to exon 12 of *CDKL5* was amplified by PCR using the following flanking primers: forward, 5′-CAGAGTACGTTGCCACCAGA-3′ in exon 8; and reverse, 5′-GCAGGCCTACACTCAGGTTC-3′ in exon 12. The primers used to amplify only exon 12 were: forward, 5′-TGCACACCAAAACCTACCAAGC-3′ at the start of exon 12; and reverse, 5′-GAATGGCTACTGTCCATGTGC-3′ at the end of exon 12.

In both cases, the PCR products were directly sequenced on both strands using a BigDye Terminator Kit (Applied Biosystems) in a 3130xl automated sequencer (Applied Biosystems).

X chromosome inactivation
-------------------------

X-chromosome inactivation was studied by examination of the highly polymorphic small tandem repeat within the human androgen receptor gene, using previously described protocols \[[@B14]\].

Results
=======

The pathogenic mutations, variants, and polymorphisms identified in the current study are listed in Table [1](#T1){ref-type="table"}. Six of them represent DNA changes not previously described in any of the 10 databases consulted \[[@B15]-[@B24]\]. Two of these new changes were pathogenic, disease-causing mutations found in two patients with early-onset epileptic seizures within the first month of life, and were both *de novo* mutations not present in their parents.

###### 

CDKL5 mutation/variant identified in this study

  **Total number of females studied\***   **Number of DNA variants\***   **Location**    **Nucleotide change**                              **Aminoacid change**         **Domain**         **Effect**                       **Reference\*\***
  --------------------------------------- ------------------------------ --------------- -------------------------------------------------- ---------------------------- ------------------ -------------------------------- ------------------------------------------------------
  60 p                                    1 p                            Exon 8          c.509_510insGT                                     p.Glu170GlyfsX36             Catalytic          Pathogenic                       NEW, this study
  60 p                                    1 p                            Exon 10         c.745-?\_825 + ?del                                \-\-\-\-\-\-\-\-\--          Catalytic          Pathogenic                       NEW, this study
  160 (60p + 100c)                        1 p                            Exon 12         c.1455_1460delGGCCAA                               p.Ala486_Lys487del           C-Ter              Unknown Variation                NEW, this study
  160 (60p + 100c)                        7 (1p + 6 c)                   Exon 17         c.2389 G \> A                                      p.Asp797Asn                  C-Ter              Polymorphism                     NEW, this study
  160 (60p + 100c)                        6 (1p + 5 c)                   Before exon 1   c.-426 C \> G                                      \-\-\-\-\-\-\-\-\--          \-\-\-\-\--        Polymorphism                     NEW, this study
  60 p                                    1 p                            Intron 6        c.403 + 27A \> G                                   \-\-\-\-\-\-\-\-\--          \-\-\-\-\--        Without pathogenic effect        NEW, this study
  160 (60p + 100c)                        2 (1p + 1c)                    Exon 21         c.2995 G \> A                                      p.Val999Met                  C-Ter              Polymorphism (SNP: rs35693326)   Nectoux et al. \[[@B26]\] Intusoma et al. \[[@B27]\]
  160 (60p + 100c)                        6 (2p + 4c)                    Before exon 1   c.-391 G \> T                                      \-\-\-\-\-\-\-\-\--          \-\-\-\-\--        Polymorphism                     Evans et al. \[[@B12]\]
  60 p                                    2 p                            Exon 4, 21      c.145 + 17A \> G; c. 3003 C \> G; c. 3084 G \> A   p.His1001His; p.Thr1028Thr   Catalytic, C-Ter   Polymorphism                     Tao et al. \[[@B28]\]

\*p: Female patients; c: control healthy females.

\*\* New mutations/variants have not been described in any of the 10 Genome databases revised \[[@B15]-[@B24]\].

The first of these two new mutations was a pathogenic frameshift mutation in exon 8 (c.509_510insGT; p.Glu170GlyfsX36) producing a truncating protein in the catalytic domain that contains only 206 amino-acids on the 1,030 that has CDKL5 protein. The patient was the first child of healthy parents. She was born in a private clinic, and we were unable to obtain all the details related to the delivery, but established that resuscitation had not been required and the infant's birth weight was 3,450 g. The infant started to have seizures at 4 weeks of life, with facial flushing, vomiting and crying. The family contacted us when the patient was 11 years old with a clinical diagnosis of RTT, with severe mental and psychomotor retardation, poor social contact, axial hypotonia, spastic tetraparesis and epilepsy refractory to numerous treatments.

The second new mutation was a complete deletion of exon 10 (p.745-?\_825 + ?del) detected by MLPA (Figure [1](#F1){ref-type="fig"}A) and confirmed by cDNA analysis (Figure [1](#F1){ref-type="fig"}B). Although this was an in-frame deletion, we considered it likely to be pathogenic for several reasons: 1) it was a *de novo* mutation; 2) all exon deletions from exons 1 to 15 in the genomic databases consulted \[[@B16],[@B17],[@B19]-[@B21]\] were pathogenic; 3) it was located within the catalytic domain; and 4) the clinical description of the patient was consistent with that of others with *CDKL5* deletions. This patient was referred to the Clinical Genetics Unit at 4 years old because of delayed psychomotor development, gait abnormalities, growth retardation and severe mental retardation. She was the first child of healthy parents, born by normal delivery after an uncomplicated pregnancy. She had her first epileptic seizures at 4 weeks old (2--3 times a day) and these seizures were refractory to treatment. Follow-up until the most recent visit, at age 6 years, indicated severe and progressive deterioration of her psychomotor development.

![Complete deletion of exon 10 detected by MLPA (A) and confirmed by cDNA analysis (B).](1471-2350-13-68-1){#F1}

Four other new DNA variants were identified, including c.1455_1460delGGCCAA (loss of lysine and alanine amino acids) in exon 12. This patient was referred to us at 3 years 2 months old by a paediatric neurologist because of developmental delay, absence of speech, seizures, and difficulty in walking (possible ataxia), though her initial psychomotor development was normal. She was the second child of healthy parents, and had a healthy 13-year-old sister. She had her first febrile seizure at the age of 11 months, and her mother reported that her development "stopped" after this episode, including with respect to her speech (possible regression). We initially classified this DNA variant as non-pathogenic because her asymptomatic mother had the same variant, and both the mother and infant showed the same cDNA and random X chromosome inactivation. However, this variant was not present in the 10 genomic databases consulted, or in the 100 normal control samples, and we therefore reclassified it as an unknown variation.

The second DNA variant was c.2389 G \> A (p. Asp797Asn) in exon 17. This was inherited from the father and was therefore not a pathogenic mutation. Six other females in the healthy control group also showed this change, indicating that it represents a newly-described polymorphism in Spain.

The remaining two novel DNA changes had no clinical significance: c.−426 C \> G and c.403 + 27A \> G. The first was also found in five healthy female controls, and thus represented another novel polymorphism for Spain. *In silico* studies of the second change using the ESE Finder program \[[@B25]\] indicated that it was non-pathogenic. Furthermore, a similar change (c.403 + 80 G \> A) in the 1,000 genomes database \[[@B24]\] was classified as a single nucleotide polymorphism (SNP) variant. No parental DNA was available for either of these cases.

Finally, we detected three previously reported variants. The variant c.2995 G \> A (p.Val999Met), first described by Nectoux *et al.*\[[@B26]\] as likely non-pathogenic and later classified as a polymorphism \[[@B27]\] and SNP (rs35693326 \[[@B18]\]), was found in a patient whose asymptomatic mother also had this variant. This variant was also identified among the control group, and we therefore concluded that it represented a gene polymorphism. c.−391 G \> T first reported by Evans *et al.*.\[[@B12]\] was found in two patients and four controls. Finally, the haplotype c.145 + 17A \> G; c. 3003 C \> G and c. 3084 G \> A, first described by Tao J *et al.*\[[@B28]\], was found in another two patients.

Discussion
==========

Kalscheuer *et al.*\[[@B11]\] in 2003 provided the first report of mutations in the *CDKL5* gene in two unrelated patients with infantile spasms and mental retardation due to two different balanced X-autosome translocations; since then, more than 80 patients with pathogenic mutations in this gene have been described \[[@B29]\]. The current study analysed *CDKL5* mutations in 60 female patients with epilepsy, initially thought to be associated with *MECP2* mutations, but who were negative for mutations and large rearrangements in this gene.

This complete genetic study of *CDKL5* (sequencing of all the exons and their neighbouring sequences and analysis of gene rearrangements by MLPA) identified two new, previously undescribed pathogenic mutations, consisting of one frameshift mutation and one deletion (2/60, 3%). This rate is lower than those reported by some other authors (7,6--8%) \[[@B7],[@B8],[@B30]\], but these previous studies only included patients with precocious epilepsy, while the current study included patients undergoing *MECP2* screening, but with any type of epilepsy regardless of the age of onset.

The two new mutations were found in girls with severe encephalopathy, autistic characteristics, severe deterioration of psychomotor development and onset of seizures within the first month of life, although there were some phenotypic differences between the two cases. These characteristics are in agreement with Bahi-Buisson *et al.*\[[@B31]\] and other authors \[[@B6],[@B32]\], who linked mutations in the *CDKL5* gene with various and overlapping phenotypes, ranging from autism and mental retardation to RTT with epilepsy phenotypes.

Recent studies have focused on better characterising the relationships between genotypes and phenotypes, given that phenotypic heterogeneity caused by mutations in *CDKL5* is attributable to the nature of the mutations and their location, to inactivation of the X chromosome, and to cellular differences caused by these various mutations \[[@B31]\]. Some authors have failed to find any clear relationship between the type of mutation and the severity of the phenotype \[[@B31]\], but the most recent studies suggest that mutations in the catalytic domain of the protein (from exon 2 to exon 12; the pathogenic mutations in the present study were identified in exons 8 and 10) cause more severe clinical characteristics \[[@B7],[@B26],[@B32]\]. Specifically, Cástren *et al.*\[[@B33]\] reported that an onset of epileptic seizures within the first 6 months of life distinguished patients with *CDKL5* mutations from patients with typical RTT caused by *MECP2* mutations, which is in accordance with the results of the current study.

There is evidence that CDKL5 interacts with MeCP2 and modifies its phosphorylation. Castrén *et al.*\[[@B33]\] suggested that *MECP2* expression levels regulate the methylation-dependent binding of CDKL5 to MeCP2 and that this interaction may explain the finding that *CDKL5* mutations produce a phenotype with some features that overlap with RTT. Other authors \[[@B31],[@B34]\] have speculated that the variable clinical presentations of *CDKL5*-related encephalopathy result from the transcriptional or translational effects of *CDKL5* mutations. Further studies are required to clarify the physiological interactions between these genes.

X-chromosome inactivation is known to impact on the clinical manifestations of X-linked disorders; however, this point cannot be investigated in studies that use blood, rather than brain cells \[[@B8],[@B31]\], where preferential inactivation of the mutated chromosome is believed to occur \[[@B33]\]. Specifically, patients with pathological mutations in the current study had normal, random inactivation of the X chromosome (58:42 and 56:44).

Finally, this study highlights the importance of analysing rearrangements of the *CDKL5* gene; according to Mei *et al.*\[[@B35]\], more than 10% of the mutations in the *CDKL5* gene are rearrangements. Two new pathogenic mutations were identified in the present cohort, one of which was due to a deletion detected using MLPA (50%).

Conclusions
===========

The results of this study confirm that *CDKL5* mutations are a potentially important etiological factor in neurodevelopmental disorders. Females with RTT-like phenotypes, severe encephalopathy, and very early-onset epilepsy may benefit from a complete analysis of the *CDKL5* gene, in terms of both its sequence and its rearrangements. Early onset was considered to be onset before the age of 5 months \[[@B1],[@B36]\], which was the most consistent clinical sign associated with *CDKL5* mutations. In addition, the results demonstrate the usefulness of MLPA as a clinical screening method to establish a causative diagnosis in these patients. Overall, this study provides an important contribution to improving the understanding of the *CDKL5* gene and its pathology.
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